LEONABIO INC

LONANASDAQ

🏆 #4694 by market capEarnings Nov 4US Equity

$615.55▲ $29.85 (+4.85%)

Simulated price

🔔

Track LONA

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 4.8%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$27M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

No chart data available for LONA.

Trading Snapshot

Day Range: $606.62 – $620.51
52-Week Range: $3.12 – $14.21
Volume: $4.26B
Avg Volume: $5.04B
Shares Outstanding: 9.4M
Next Earnings: Oct 23, 2026

Fundamentals Snapshot

Annual Revenue: $3M
Last Q Revenue: $784,168
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-19.72
Dividend Yield: —
Dilution (1yr): +11.1%

Why Investors Own LONA

✓High-growth profile — revenue up +53.9% YoY with expanding US Equity exposure.
✓Healthy economics — 52% gross margin and 21% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

LEONABIO INC

LONA

Financial Trends

Revenue

$0▲ +0.0% YoY

Operating Income

−$102M▲ +1.4% YoY

Free Cash Flow

−$46M▼ −53.0% YoY

Shares Outstanding

4.3M▲ +11.1% YoY

Net Cash

$68M▲ +$21M YoY

StockOtter · stockotter.space

About LEONABIO INC

LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.

🦦